Posted on: November 8, 2008
Lexington International, LLC, manufacturer and distributor of the HairMax LaserComb®, the only clinically proven medical device alternative to stop thinning and regrow hair, has obtained Korean FDA approval. Lexington submitted clinical data from both male and female studies, along with ISO and GMP accreditations to achieve this approval.
Estimated Korean hair loss population to be 4.04 million (up 670,000 from the same survey result in 1999) with a men's hair loss ratio in South Korea of 22.41%. Additionally, the idea of hair loss is not as readily accepted among Koreans as compared to Western Society.
Through Lexington's ongoing commitment to clinical research and development, the HairMax LaserComb® has achieved medical device clearance by the US FDA, Health Canada, Singapore Health Authority, Israeli Ministry of Health, Russian Federation of Health, and Brazilian ANVISA.
With the advent of approval by the Korean FDA for the HairMax LaserComb®, Koreans now have a new drug free modality to grow thicker, healthier, and fuller hair in the privacy and convenience of their home.
For more information, please visit: HairMax website |
|
|
|
